Description
This section will provide an overview and understanding of:
- US Private health care plans and main trends in the industry
- Role in the industry of key stakeholders, such as Pharmacy benefit managers (PBMs)
- Characteristics of US free pricing
- Payers assessment bodies
- Payers expectations in terms of evidence and data requirements
- Payers’ toolbox to limit excessive drug pricing
- Pricing and Reimbursement timelines in USA
- The role and the rising importance of ICER, known as the US independent watchdog on drug pricing
